ReviewJournal of neuro-oncology2025
Synergy of radiotherapy, focused ultrasound, and immunotherapy in the treatment of brain metastases.
Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Potential and Challenges of Focused Ultrasound-Mediated Therapies in the Management of Liver and Biliary Tract Cancers.Cancers · 2026Review
- The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrain metastases (BrM) represent the most common intracranial malignancies and remain a major clinical challenge. Unlike glioblastoma (GBM), where immunotherapy has shown limited benefit, there are promising results for BrM. Nonetheless, several key aspects remain to be solved to amplify the success of these therapies, highlighting the potential of integrating immunotherapy with local strategies. This review focuses on therapeutic approaches for BrM, emphasizing the role of radiotherapy (RT) and focused ultrasound (FUS) in enhancing immunotherapy efficacy.
methodsWe performed a narrative review of recent clinical studies addressing the interactions between the immune system, RT, and blood–brain barrier (BBB) modulation by FUS, with an emphasis on therapeutic strategies tested in BrM.
resultsThe success of immunotherapy in brain malignancies is hindered by the immunosuppressive tumor microenvironment (TME) and limited BBB penetration, as these treatments are administered systemically. RT synergizes with immunotherapy by promoting tumor antigen release and immune priming, which helps transiently overcome the immunosuppressive TME. However, excessive and prolonged antigen exposure may lead to T-cell exhaustion and checkpoint upregulation, which explains why sequential administration of stereotactic radiosurgery (SRS) followed by immunotherapy within a 2–4-week window enhances antitumor responses. Regarding the general difficulty for systemic drugs to access the brain, FUS emerges as a potent candidate for enabling transient BBB disruption, facilitating drug delivery, and biomarker access.
conclusionCombining immunotherapy with SRS or FUS-mediated BBB modulation offers a promising path for improving outcomes in BrM. Future work must optimize these multimodal strategies while minimizing toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.